FindTrial
Sign In

AZD3293

DRUG5 trials

Sponsors

AstraZeneca

Conditions

Alzheimer's DiseaseHealthy Elderly VolunteersHealthy Japanese Young and Elderly Male and Non-fertile Female VolunteersHealthy VolunteersHealthy Young VolunteersMass Balance StudyMild-to-moderate Alzheimer's Disease Patients

Phase 1

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects
CompletedNCT01739647
AstraZenecaHealthy Elderly Volunteers, Healthy Young Volunteers
Start: 2012-12-31End: 2013-05-31Updated: 2013-08-27
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
CompletedNCT01795339
AstraZenecaHealthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
Start: 2013-03-31End: 2014-03-31Updated: 2014-04-03
A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers
CompletedNCT02005211
AstraZenecaHealthy Japanese Young and Elderly Male and Non-fertile Female Volunteers
Start: 2013-12-31End: 2014-07-31Updated: 2016-11-04
AZD3293 Thorough QT Study in Healthy Male Volunteers
CompletedNCT02040987
AstraZenecaAlzheimer's Disease
Start: 2014-01-31End: 2014-05-31Updated: 2014-07-03
A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293
CompletedNCT02126514
AstraZenecaHealthy Volunteers, Mass Balance Study
Start: 2014-05-31End: 2014-05-31Updated: 2014-06-16

Related Papers

Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics
Clinical Pharmacology in Drug Development2018-01-1016 citations
BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides
The Journal of Clinical Pharmacology2017-06-1559 citations
P2‐002: Assessment of The Safety, Tolerability, Pharmacokinetics, and Effects on Plasma and Cerebrospinal Fluid AB Peptides of AZD3293, a Novel Bace1 Inhibitor, in Healthy Japanese Adults
Alzheimer s & Dementia2016-07-01
Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer's Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair.
2016-01-0114 citations